Advice
Following an abbreviated submission
Mesalazine 800 mg modified release tablet (Asacol) is accepted for use in NHS Scotland for the maintenance of remission in ulcerative colitis and Crohn’s ileo-colitis.
At the recommended dose of up to 2.4g daily, the 800 mg strength allows halving of the pill burden compared with the 400 mg formulation at no extra cost.
Download detailed advice54KB (PDF)
Medicine details
- Medicine name:
- mesalazine (Asacol)
- SMC ID:
- 224/05
- Indication:
- Maintenance of remission in ulcerative colitis and Crohn's ileo-colitis
- Pharmaceutical company
- Procter and Gamble
- BNF chapter
- Gastro-intestinal system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 11 February 2008